GOSS

Gossamer BioF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.60

Analysis reference price unavailable

Analysis 2026-09-06 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$0.24

Analysis reference price unavailable

Analysis 2026-09-06 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.08

Analysis reference price unavailable

Analysis 2026-09-06 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-06

AI commentary

News tone is moderately positive because of the September NDA plan, rights reacquisition and financing activity, but the Q2 adjusted loss miss and binary regulatory path temper conviction. Social sentiment, options skew, short interest, employee sentiment and verified analyst revisions are unavailable; missing data is not positive evidence.

RankAlpha Sentiment Codex - 2026-09-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-24catalystFinancing and runway visibilityHigh impact

Gossamer reported $57.0 million of cash, cash equivalents and marketable securities at June 30, 2026. The previously disclosed private-placement structure provides additional funding contingent on FDA acceptance and potential approval, but also introduces dilution and execution risk. [#SEC-8K-2026-08-21]

2026-09-30eventPlanned seralutinib NDA submissionHigh impact

Following FDA Pre-NDA Type B meeting minutes, Gossamer said it intends to submit an NDA for seralutinib in PAH in September 2026. Filing acceptance is not assured, and statistical significance and treatment-effect magnitude remain review issues. [#PR-EARNINGS-2026-08-13] [#SEC-8K-2026-07-27]

2027-09-30catalystConditional FDA review and approval pathHigh impact

If the NDA is accepted, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027. The outcome remains binary and depends on the FDA's review of the complete submission. [#PR-EARNINGS-2026-08-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-06 • Updated nightlySource: Internal modelMethodology